Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | KAT7 | O95251 | 2/20 | 0.36 |
| ▸ | KAT6B | Q8WYB5 | 2/20 | 0.36 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.34 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31605548 | 1.00 | MAPT (0.37) | MAPTTP53BRD4KAT7KAT6B | |
| SCHEMBL28514884 | 0.93 | BRD4 (0.38) | MAPTTP53BRD4KAT7KAT6B | |
| SCHEMBL29652474 | 0.93 | BRD4 (0.38) | MAPTTP53BRD4KAT7KAT6B | |
| SCHEMBL21596783 | 0.91 | KAT7 (0.36) | MAPTTP53BRD4KAT7KAT6B | |
| SCHEMBL21596842 | 0.91 | KAT7 (0.36) | MAPTTP53BRD4KAT7KAT6B | |
| SCHEMBL21596810 | 0.91 | TSHR (0.39) | MAPTTP53BRD4KAT7KAT6B | |
| SCHEMBL30838426 | 0.91 | KAT7 (0.36) | MAPTTP53BRD4KAT7KAT6B | |
| SCHEMBL31605563 | 0.91 | KAT7 (0.36) | MAPTTP53BRD4KAT7KAT6B | |
| SCHEMBL30838424 | 0.91 | TSHR (0.39) | MAPTTP53BRD4KAT7KAT6B | |
| SCHEMBL29652370 | 0.90 | KAT7 (0.41) | MAPTTP53BRD4KAT7KAT6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062393-A1 | Compounds | CTXT PTY LTD (AU) | 2026-03-05 | — | — | US | disclosed |
| US-12365655-B2 | Compounds | CTXT PTY LTD (AU) | 2025-07-22 | — | — | US | disclosed |
| EP-4335439-A2 | COMPOUNDS | CTXT PTY LTD (AU) | 2024-03-13 | — | — | EP | disclosed |
| EP-3810602-B1 | COMPOUNDS | CTXT PTY LTD (AU) | 2023-11-01 | — | — | EP | disclosed |
| US-20220153710-A1 | Compounds | CTXT PTY LTD (AU) | 2022-05-19 | — | — | US | disclosed |
| EP-3810602-A1 | COMPOUNDS | CTXT Pty Limited (AU) | 2021-04-28 | — | — | EP | disclosed |
| CN-112334466-A | Compound (I) | CTXT私人有限公司 | 2021-02-05 | — | — | CN | disclosed |
| US-20200039945-A1 | Compounds | CTXT PTY LIMITED (AU) | 2020-02-06 | — | — | US | disclosed |
| WO-2019243491-A1 | COMPOUNDS | CTXT PTY LIMITED (AU) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153710-A1 | Compounds | SLC10A1, ABCB11, PCSK9 | MAPT 1135/4885TP53 3501/4885BRD4 1909/4885 |
| US-20200039945-A1 | Compounds | SLC10A1, ABCB11, PCSK9 | MAPT 1136/4885TP53 3504/4885BRD4 1913/4885 |
| US-20260062393-A1 | Compounds | SCN2B, ABCB11, SCN1B | MAPT 2629/4885TP53 4584/4885BRD4 343/4885 |
| US-12365655-B2 | Compounds | SLC10A1, ABCB11, PCSK9 | MAPT 1136/4885TP53 3504/4885BRD4 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.